Search Filters:

The items contained in the list are being used to filter the search results. Click them to remove them from the search filter.
Displaying 61 - 80 of 831
PIPS Search Results
PIP Number Active Substance Conditions / Indications Invented Name Therapeutic area Decision Type Compliance Check Compliance outcome Date Published Sort ascending
MHRA-102136-PIP01-25
  • Human amylin analogue, amylin receptor selective, long-acting, N-terminally lipidated (AZD6234)
  • Treatment of obesity
  • Endocrinology-Gynaecology-Fertility-metabolism
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No
MHRA-100019-PIP01-21-M02 (update)
  • BELUMOSUDIL MESYLATE
  • Treatment of chronic Graft versus Host Disease (cGVHD)
  • Rezurock
  • Rezurock
  • Rholistiq
  • Rholistiq
  • Rezurock
  • Rezurock
  • Rezurock
  • Rezurock
  • Rezurock
  • Rezurock
  • Rezurock
  • Rezurock
  • Rezurock
  • Rezurock
  • Rezurock
  • Rezurock
  • Rezurock
  • Rezurock
  • Rezurock
  • Rezurock
  • Immunology -Rheumatology-Transplantation
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-100678-PIP01-22-M02 (update)
  • Vamikibart
  • Treatment of uveitic macular oedema
  • Ophthamology
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-102273-PIP01-25
  • EZETIMIBE
  • ATORVASTATIN
  • Treatment of hypercholesterolaemia
  • Prevention of cardiovascular events
  • Ezetimibe/Atorvastatin 10mg/10mg Film-coated Tablets
  • Ezetimibe/Atorvastatin 10mg/20mg Film-coated Tablets
  • Ezetimibe/Atorvastatin 10mg/40mg Film-coated Tablets
  • Ezetimibe/Atorvastatin 10mg/80mg Film-coated Tablets
  • Cardiovascular Diseases
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-102153-PIP01-25
  • Human IgG1 monoclonal antibody against folate receptor alfa conjugated to samrotecan
  • Treatment of ovarian cancer, fallopian tube cancer and peritoneal cancer.
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-102137-PIP01-25
  • izalontamab brengitecan
  • Treatment of lung cancer
  • Treatment of breast cancer
  • Treatment of urothelial carcinoma
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-100556-PIP02-25
  • Riliprubart
  • Treatment of rejection of a transplanted kidney
  • Neurology
  • Immunology -Rheumatology-Transplantation
  • Haematology-Hemostaseology
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No
MHRA-100993-PIP01-23-M03 (update)
  • QUIZARTINIB DIHYDROCHLORIDE
  • Treatment of acute myeloid leukaemia
  • VANFLYTA
  • VANFLYTA
  • Oncology
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-102046-PIP01-25
  • Pegozafermin
  • Treatment of metabolic dysfunction-associated steatohepatitis (MASH).
  • Gastroenterology-Hepatology
  • Endocrinology-Gynaecology-Fertility-metabolism
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No
MHRA-101705-PIP01-24
  • Elamipretide
  • Treatment of Barth syndrome
  • Not available at present
  • Endocrinology-Gynaecology-Fertility-metabolism
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No
MHRA-100957-PIP01-23-M01 (update)
  • deucravacitinib
  • Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis & juvenile idiopathic arthritis)
  • SOTYKTU
  • SOTYKTU
  • SOTYKTU
  • SOTYKTU
  • SOTYKTU
  • SOTYKTU
  • SOTYKTU
  • SOTYKTU
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-101901-PIP01-25
  • Golcadomide
  • Treatment of mature B cell neoplasms
  • Haematology-Hemostaseology
  • Oncology
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No
MHRA-101094-PIP01-23-M02 (update)
  • GIVINOSTAT HYDROCHLORIDE MONOHYDRATE
  • Treatment of Duchenne muscular dystrophy
  • Duvyzat
  • Duvyzat 8.86 mg/ml oral suspension
  • Neurology
  • Other: Other drugs for disorders of the musculo-skeletal system
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-100059-PIP01-21-M02 (update)
  • roxadustat
  • Treatment of anaemia due to chronic disorders
  • EVRENZO
  • EVRENZO
  • EVRENZO
  • EVRENZO
  • Ivrenzo
  • EVRENZO
  • EVRENZO
  • Evrenzo Tablets
  • EVRENZO
  • EVRENZO
  • Haematology-Hemostaseology
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-100811-PIP01-22-M04 (update)
  • Vamorolone
  • Treatment of Duchenne muscular dystrophy
  • AGAMREE
  • AGAMREE
  • AGAMREE
  • AGAMREE
  • AGAMREE
  • AGAMREE
  • AGAMREE
  • AGAMREE
  • Neurology
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-101846-PIP01-25
  • budigalimab
  • Treatment of all conditions inc. in the category of malignant neoplasms except melanoma, CNS neoplasms, haematopoietic and lymphoid tissues neoplasms
  • Not available at present
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-100129-PIP01-21-M03 (update)
  • Cipaglucosidase alfa
  • Treatment of glycogen storage disease Type II (Pompe's disease)
  • Pombiliti
  • Pombiliti
  • Pombilti
  • Pomiliti
  • Pombiliti
  • Pombiliti
  • Endocrinology-Gynaecology-Fertility-metabolism
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-102204-PIP01-25
  • pasritamig
  • Treatment of prostate malignant neoplasms
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-100949-PIP01-23-M03 (update)
  • delandistrogene moxeparvovec
  • Treatment of Duchenne Muscular Dystrophy.
  • Neurology
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-102297-PIP01-25
  • imlunestrant
  • Treatment of breast malignant neoplasms
  • Inluriyo
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No